Home / Resources / The New Standard: How AI Is Reshaping Trial Design, Execution, and Disclosure
STRATEGIC PLAYBOOK | Sept. 25, 2025

The New Standard: How AI Is Reshaping Trial Design, Execution, and Disclosure

This strategic playbook offers a blueprint for how leading teams are adopting AI in practical, measurable ways, from protocol feasibility and cohort modeling to clinical trial disclosure and transparency.

Download the playbook to learn more.

PDF preview of The New Standard: How AI Is Reshaping Trial Design, Execution, and Disclosure playbook, available for download.
Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.
Related products
''
Protocol SmartDesign
Get a head start on your primary endpoints and I/E criteria
''
Investigator SmartSelect
Quickly generate a list of investigators best fit for your trial
Professionals accessing TrialScope Disclose to track trial compliancy and awareness of regulations.
TrialScope Disclose
Manage the complexity of clinical trial disclosure and the risk of non-compliance by automating data entry and reporting to registries

Related resources

Preview cover for the Intelligent Compliance: Transforming Clinical Trial Disclosure with AI white paper
NOV 04, 2024
White paper
Regulatory & Compliance

Intelligent Compliance: Transforming Clinical Trial Disclosure with AI

AI can help sponsors streamline clinical trial disclosure processes and meet the growing demands for timely and accessible information.

AI
OCT 11, 2024
White paper
Clinical

AI in Pharma: Benefits, Risks, and the Road Ahead

AI is being used to streamline and accelerate each step of the drug development process from research through approval and marketing.

AI assistant in biotechnology science experiment
JUL 15, 2024
Article
Clinical

The Promise and Peril of AI in Clinical Trials

Many smaller organizations have not yet implemented a specialized clinical trial disclosure system. Robust transparency, and perhaps even just compliance with multiple regulators, requires commitment from the C-suite for companies of all sizes.

View all